CN101120018B - 绿脓假单胞菌iats o11血清型脂多糖（lps）特异性人单克隆抗体 - Google Patents

绿脓假单胞菌iats o11血清型脂多糖（lps）特异性人单克隆抗体 Download PDF

Info

Publication number
CN101120018B
CN101120018B CN2006800048470A CN200680004847A CN101120018B CN 101120018 B CN101120018 B CN 101120018B CN 2006800048470 A CN2006800048470 A CN 2006800048470A CN 200680004847 A CN200680004847 A CN 200680004847A CN 101120018 B CN101120018 B CN 101120018B
Authority
CN
China
Prior art keywords
monoclonal antibody
human monoclonal
antibody
pseudomonas aeruginosa
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2006800048470A
Other languages
English (en)
Chinese (zh)
Other versions
CN101120018A (zh
Inventor
A·B·朗
M·P·霍恩
M·A·英博登
A·齐歇尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kenta Biotech AG
Original Assignee
Kenta Biotech AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kenta Biotech AG filed Critical Kenta Biotech AG
Publication of CN101120018A publication Critical patent/CN101120018A/zh
Application granted granted Critical
Publication of CN101120018B publication Critical patent/CN101120018B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1214—Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN2006800048470A 2005-02-14 2006-02-13 绿脓假单胞菌iats o11血清型脂多糖（lps）特异性人单克隆抗体 Expired - Fee Related CN101120018B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05003095A EP1690875A1 (en) 2005-02-14 2005-02-14 Human monoclonal antibody specific for lipopolysaccharides (LPS) of the pseudomonas aeruginosa IATS O11 serotype
EP05003095.6 2005-02-14
PCT/EP2006/001289 WO2006084758A1 (en) 2005-02-14 2006-02-13 Human monoclonal antibody specific for lipopolysaccharides (lps) of the pseudomonas aeruginosa iats o11 serotype

Publications (2)

Publication Number Publication Date
CN101120018A CN101120018A (zh) 2008-02-06
CN101120018B true CN101120018B (zh) 2012-07-25

Family

ID=34933741

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2006800048470A Expired - Fee Related CN101120018B (zh) 2005-02-14 2006-02-13 绿脓假单胞菌iats o11血清型脂多糖（lps）特异性人单克隆抗体

Country Status (11)

Country Link
US (1) US8197816B2 (https=)
EP (2) EP1690875A1 (https=)
JP (1) JP4944799B2 (https=)
KR (2) KR20070107756A (https=)
CN (1) CN101120018B (https=)
AT (1) ATE480563T1 (https=)
CA (1) CA2597701C (https=)
DE (1) DE602006016736D1 (https=)
ES (1) ES2348263T3 (https=)
IL (1) IL184774A (https=)
WO (1) WO2006084758A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105849262A (zh) * 2013-09-30 2016-08-10 第三共株式会社 抗lps o11抗体

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2571673A1 (en) * 2004-06-28 2006-01-05 Proteome Systems Intellectual Property Pty Ltd Novel methods of diagnosis of treatment of p. aeruginosa infection and reagents therefor
EP2417157A1 (en) * 2009-04-09 2012-02-15 Kenta Biotech AG Human monoclonal antibody specific for lipolysaccarides (lps) of serotype lats 01 of pseudomonas aeruginosa
KR20120128686A (ko) * 2010-02-18 2012-11-27 심포젠 에이/에스 녹농균의 혈청형 ａ 지질다당류에 대한 항체
EP2361989A1 (en) * 2010-02-26 2011-08-31 Kenta Biotech AG Assays and kits for serotyping Pseudomonas aeruginosa and oligonucleotide sequences useful in such methods and kits
WO2017083515A2 (en) 2015-11-10 2017-05-18 Visterra, Inc. Antibody molecule-drug conjugates and uses thereof
JP7303110B2 (ja) 2017-01-18 2023-07-04 ビステラ， インコーポレイテッド 抗体分子－薬物コンジュゲートおよびその使用
KR20240085798A (ko) 2020-04-03 2024-06-17 비스테라, 인크. 항체 분자-약물 접합체 및 이의 용도
EP4512826A3 (en) 2021-07-09 2025-04-02 Luxembourg Institute Of Health (LIH) Dimeric protein complexes and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5627067A (en) * 1985-12-10 1997-05-06 Bristol-Myers Squibb Company Monoclonal antibodies cross-reactive and cross-protective against human monoclonal antibodies against pseudomonas aeruginosa serotypes

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4398620B2 (ja) 2000-02-03 2010-01-13 ミレニアム・ファーマシューティカルズ・インコーポレイテッド ヒト化抗ｃｃｒ−２抗体およびその使用方法
EP1319025A2 (en) * 2000-09-07 2003-06-18 John R. Schreiber Human antibodies against pseudomonas aeruginosa lps derived from transgenic xenomouse

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5627067A (en) * 1985-12-10 1997-05-06 Bristol-Myers Squibb Company Monoclonal antibodies cross-reactive and cross-protective against human monoclonal antibodies against pseudomonas aeruginosa serotypes

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
H. Francisco等.Pharmacokinetics, tolerability, and priliminaryefficacy of human anti-Pseudomonas aeruginosa monoclonalantibidies in pneumonia and burn infection patients.Hybridoma第16卷 第5期.1997,第16卷(第5期),413-420.
H. Francisco等.Pharmacokinetics, tolerability, and priliminaryefficacy of human anti-Pseudomonas aeruginosa monoclonalantibidies in pneumonia and burn infection patients.Hybridoma第16卷 第5期.1997,第16卷(第5期),413-420. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105849262A (zh) * 2013-09-30 2016-08-10 第三共株式会社 抗lps o11抗体

Also Published As

Publication number Publication date
EP1690875A1 (en) 2006-08-16
JP2008530988A (ja) 2008-08-14
DE602006016736D1 (de) 2010-10-21
KR20070107756A (ko) 2007-11-07
ATE480563T1 (de) 2010-09-15
IL184774A0 (en) 2007-12-03
EP1848741A1 (en) 2007-10-31
US20090068191A1 (en) 2009-03-12
EP1848741B1 (en) 2010-09-08
ES2348263T3 (es) 2010-12-02
KR20130018991A (ko) 2013-02-25
JP4944799B2 (ja) 2012-06-06
CA2597701A1 (en) 2006-08-17
CN101120018A (zh) 2008-02-06
IL184774A (en) 2012-01-31
US8197816B2 (en) 2012-06-12
CA2597701C (en) 2012-01-10
WO2006084758A1 (en) 2006-08-17

Similar Documents

Publication Publication Date Title
CN101928343B (zh) 针对clfa蛋白质的单克隆抗体和在治疗或预防感染中的利用方法
CN102549013A (zh) 针对金黄色葡萄球菌衍生的α-毒素的人单克隆抗体及其在治疗或预防脓肿形成中的用途
CN107868128A (zh) 抗tlr4抗体及其用途
DE69010001T2 (de) Synthetisches pseudomonas aeruginosa pilin-peptid und verwandte impfstoffe und diagnostika.
IL184774A (en) Human monoclonal antibody specific for lipopolysaccharides (lps) of the pseudomonas aeruginosa iats 011 serotype
KR20150073211A (ko) 항―캄필로박터 제주니 항체 및 그의 용도
EP1479695B1 (en) Human monoclonal antibody specific for lipopolysaccharides (LPS) of serotype IATS O6 of Pseudomonas aeruginosa
EP0567470B1 (en) Pseudomonas peptide composition and method for producing the same
US20120114657A1 (en) Human Monoclonal Antibody Specific for Lipopolysaccharides (LPS) of Serotype IATS 01 of Pseudomonas Aeruginosa
CN112159470B (zh) 一种抗wnv感染的结合分子
Troisi et al. Human monoclonal antibodies reveal subdominant gonococcal and meningococcal cross-protective antigens
KR100506118B1 (ko) 수막염균증 백신 조성물
CA2379129A1 (en) Fima pilus-based vaccines

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20120725

Termination date: 20210213